Health Sciences Center
|
Louisiana State University Health Sciences Center |
Critical Care Medicine |
| Home | | | Faculty | | | Clinical | | | Education | | | Fellowship | | | ECLS/ECMO | | | Research | | | Site Map |
The Clinical Research section of the Division conducts a number of clinical trials at LSUHSC in the critically ill patient population. Currently trials are being conducted in the following areas:
The research section is listed with CenterWatch at the following location: http://www.centerwatch.com/professional/pro1245.html
How to contact us: |
call schedule |
| Research Coordinators | Physician Investigators |
|---|---|
|
Kim Hutchinson, RN, BSN, CCRN, CLNC Office location: 8-J-18 Office phone: 318-675-6682 Mobile: 318-773-0601 |
Steven Conrad, MD PhD, CCRI Office location: 8-J-18 Office phone: 318-675-6660 Pager: 318-632-3352 |
|
Stephanie Self, RN, BSN Office location: 8-J-18 Office phone: 318-675-6660 Mobile: 318-332-1467 |
Laurie Grier, MD Office location: 6-B-390 Office phone: 318-675-5920 Pager: 318-675-7007 x0756 |
|
Lisa Caskey, RN, BSN, CCRC Office location: 8-J-18 Office phone: 318-675-6660 Mobile: 318-426-0535 |
L. Keith Scott, MD Office location: Clinical Research Building Office phone: 318-675-6686 Pager: 318-675-7007 x0498 Mobile: 318-218-7150 |
Safety and efficacy of continuous infusion of a cytokine inhibitor in severe sepsis |
|
| Eligibility | Patients with known or suspected infection and severe sepsis (sepsis with organ failure. |
| Outcomes | Evaluate effects on organ dysfunction and 28-day mortality |
Safety and efficacy of a new agent for severe community-acquired pneumonia |
|
| Eligibility | Patients with severe community-acquired pneumonia |
| Outcomes | Evaluate effects on pulmonary injury and 28-day mortality |
Intrapulmonary installation of a treatment for severe community acquired pneumonia |
|
| Eligibility | Patients with severe community-acquired pneumonia or aspiration pneumonitis resulting in respiratory failure |
| Outcomes | Evaluate effects on ventilator-induced lung injury and mortality |
Lipid-lowering agents in acute coronary syndromes |
|
| Eligibility | Patients with acute myocardial ischemia, myocardial infarction, or unstable angina |
| Outcomes | Evaluate effects on mortality and re-occurrence of cardiac events |
Comparison of a new agent with intravenous midazolam for ICU sedation |
|
| Eligibility | Patients requiring ICU stay > 3 days and mechanical ventilation |
| Outcomes | Evaluate effects on sedation scores and ICU length of stay |